This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Thermo Fisher Scientific is a scientific instrument maker and a world leader in serving science. In Nov 2006, Thermo Fisher Scientific, Inc. was formed through the merger of Thermo Electron Corporation with Fisher Scientific International Inc. On Feb 3, 2014, Thermo Fisher acquired Life Technologies Corporation. Following the acquisition, the new reporting segments are: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services.
The Zacks Analyst Blog Highlights: Microsoft, Visa, Cisco, Berkshire Hathaway and Thermo Fisher Scientific
by Zacks Equity Research
Microsoft, Visa, Cisco, Berkshire Hathaway and Thermo Fisher Scientific are included in this analyst blog.
Rise in COVID Tests to Boost Thermo Fisher (TMO) Q4 Earnings
by Zacks Equity Research
With the emergence of the Omicron variant through the Q4 months globally, Thermo Fisher's (TMO) Life-Science Solutions segment is likely to have registered strong top-line contributions.
Top Research Reports for Microsoft, Visa & Cisco
by Sheraz Mian
Today's Research Daily features new research reports on 16 major stocks, including Microsoft Corporation (MSFT), Visa Inc. (V), and Cisco Systems, Inc. (CSCO).
Thermo Fisher Scientific (TMO) Stock Moves -0.88%: What You Should Know
by Zacks Equity Research
In the latest trading session, Thermo Fisher Scientific (TMO) closed at $588.16, marking a -0.88% move from the previous day.
Here's Why You Should Retain Thermo Fisher (TMO) Stock for Now
by Zacks Equity Research
Investors are optimistic about Thermo Fisher's (TMO) strong end-market growth and focus on international regions.
Should You Invest in the Fidelity MSCI Health Care Index ETF (FHLC)?
by Zacks Equity Research
Sector ETF report for FHLC
Thermo Fisher Scientific (TMO) Outpaces Stock Market Gains: What You Should Know
by Zacks Equity Research
Thermo Fisher Scientific (TMO) closed the most recent trading day at $625.20, moving +0.76% from the previous trading session.
Will Thermo Fisher (TMO) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Thermo Fisher (TMO) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Thermo Fisher (TMO) Completes Buyout of PeproTech for $1.85B
by Zacks Equity Research
Thermo Fisher's (TMO) recent acquisition will boost its capabilities to serve in the high-growth cell and gene therapy market.
Thermo Fisher Scientific (TMO) Gains As Market Dips: What You Should Know
by Zacks Equity Research
Thermo Fisher Scientific (TMO) closed the most recent trading day at $620.40, moving +0.3% from the previous trading session.
Hologic's (HOLX) GAI Program to Include Aptima SARS-CoV-2 Assay
by Zacks Equity Research
The addition of Aptima SARS-CoV-2 assay to Hologic's (HOLX) Global Access Initiative is likely to improve its accessibility.
Here's Why You Should Retain Stryker (SYK) Stock Right Now
by Zacks Equity Research
Stryker (SYK) continues to benefit from strength in the robotic-arm assisted surgery platform, Mako, and broad product portfolio. However, pricing pressure remains a concern.
PacBio (PACB) Ties Up to Boost Rare Disease Diagnosis in Canada
by Zacks Equity Research
PacBio's (PACB) recent partnership with Care4Rare, with regard to a study, has the potential to enhance rare disease diagnosis within Canada.
4 Stocks to Watch Out For as MedTech Rides on Buyout Frenzy
by Debanjana Dey
Here are some MedTech stocks - Quidel (QDEL), Thermo Fisher (TMO), Baxter (BAX) and BD (BDX) - that have been quite active in the acquisition front and therefore worth investor attention.
STERIS (STE) Hits a New 52-Week High: What's Driving It?
by Zacks Equity Research
Strong segmental performances are driving the top line for STERIS (STE).
3 Reasons to Retain Integer Holdings (ITGR) Stock For Now
by Zacks Equity Research
Investors continue to be optimistic about Integer Holdings (ITGR) owing to its improving non-medical sales and solid foothold in the broader MedTech space.
Here's Why You Should Retain Cardinal Health (CAH) Stock Now
by Zacks Equity Research
Cardinal Health (CAH) continues to gain traction from the solid pharmaceutical segment and diversified product portfolio. However, contraction in gross margin is a woe.
Nevro's (NVRO) 10 kHz Therapy for Treatment of PDN Gets Coverage
by Zacks Equity Research
Nevro (NVRO) receives coverage for its high-frequency 10 kHz therapy for the treatment of PDN.
Here's Why You Should Hold on to Bruker (BRKR) Stock for Now
by Zacks Equity Research
Investors are optimistic about Bruker's (BRKR) growth in the BioSpin Group and CALID Group.
Here's Why You Should Retain Phibro (PAHC) Stock for Now
by Zacks Equity Research
Investors are optimistic about Phibro (PAHC), given robust performance by its nutritional specialties and vaccine product lines.
Illumina (ILMN) Ties Up With Syapse to Evaluate Biomarker Testing
by Zacks Equity Research
Illumina's (ILMN) recent collaboration will explore the real-world uptake and actionability of comprehensive genomic profiling in patients with advanced cancer.
Omnicell (OMCL) to Expand EnlivenHealth Division With New Buyout
by Zacks Equity Research
Omnicell's (OMCL) $82-million buyout of MarkeTouch Media is likely to expand its Advanced Services portfolio.
Zacks.com featured highlights include: Toll Brothers, Microsoft, Avery Dennison, J.B. Hunt, and Thermo Fisher
by Zacks Equity Research
Zacks.com featured highlights include: Toll Brothers, Microsoft, Avery Dennison, J.B. Hunt, and Thermo Fisher.
Here's Why You Should Retain LHC Group (LHCG) Stock Now
by Zacks Equity Research
LHC Group (LHCG) continues to benefit from strategic deals and a broad array of services.
5 Unbeatable Dividend Growth Stocks for 2022
by Sweta Killa
Beat the market with dividend stocks like Toll Brothers (TOL), Microsoft (MSFT), Avery Dennison (AVY), J.B. Hunt (JBHT) and Thermo Fisher (TMO) in 2022.